The safety of percutaneous coronary interventions (PCI) performed in centers without surgical back-up is controversial, but data from several western coun tries indicates that this approach can be extended to a larger number of hospitals. We assessed the safety and efficacy of performing angiography and PCI with a mobile Carm angiograph in a center without on-site surgical back-up, and compared our data with that reported in the literature.
C oronary angiography is the gold standard in diagnosing coronary artery disease (CAD), but it is expensive. Technological innovations now allow mobile angiographs to compete with conventional stationary machines. Percutaneous coronary interventions (PCI) are an important part of diagnosis in cardiovascular disorders. The need for cheap but powerful angiographs will increase in the future. A topic of debate is the safety issue of PCI performed in centers without surgi cal back-up. Although PCI is recommended for the man agement of acute myocardial infarction (AMI) and refrac tory unstable angina, less than 10% of European hospitals are equipped with PCI facilities. Some are equipped with mobile fluoroscopy machines and even less have on-site cardiac surgery back-up.1,2
A meta-analysis of ten multicenter randomized tri als indicated that primary angioplasty in AMI lowers the rates of death, stroke, recurrent ischemia and re-infarction compared with fibrinolytic therapy.3 In addition, for low risk patients with AMI, the mortality of primary angio plasty can be very low (<0.5%), and hospital costs can be decreased. 4 Furthermore, most AMI patients are not candidates for fibrinolytic therapy, either because they have bleeding risks or shock, or do not have diagnostic electro cardiograms (ECGs).5 These subgroups of patients may be at higher risk than those eligible to receive fibrinolytic therapy. The invasive approach can be applied to almost all of these patients at capable centers. Moreover, primary angioplasty may be more cost-effective than fibrinolytic therapy. Thus it becomes increasingly important, for both clinical and economic reasons, to address the question of whether interventional approaches to the treatment of AMI can be extended safely and effectively to a larger number of hospitals, including ones without on-site surgical back-up. This is especially important for underdeveloped countries, where stationary angiographs and cardiac surgery centers are rare and are found only in heavily populated cities, and are therefore difficult to reach for patients living in remote areas. Can mobile angiographs in hospitals without surgi cal back-up facility solve the problem? The new generation of radiological mobile systems have the ability to obtain good quality images at low cost and will be used intensively in the future. However, guidelines on the use of mobile angiographs in centers without surgical back-up facilities have limitations. We analyzed the safety and efficacy of diagnostic and therapeutic interventions performed with the use of a C-arm mobile equipment in a center without surgical back-up.
Patients and m ethods
Between January 2001 and April 2003, 1485 coronary angiography and 172 PCI procedures were performed in our center with the use of the mobile angiograph (Table  1) . Fifteen pacemakers and one ICD were also implanted. The indications for coronary angiography were consistent with American Heart Association/American College of Cardiology (AHA/ACC) guidelines for coronary indica tions published in 1987. Patients signed a written consent informing them about the status of the laboratory and pos sible complications.
The study population with AMI underwent primary an gioplasty when there was more than 30 minutes of ischemic pain not controlled by conventional medications (aspirin, nitroglycerin, beta-adrenergic blocking agents and heparin, but not fibrinolytic agents) or an ECG demonstrating 2.0 mV of ST segment elevation in two or more contiguous leads. There was no time cutoff if the clinical impression suggested ongoing myocardial necrosis (ongoing chest pain and ST deviation with preserved R waves in two or more infarct leads). Patients who presented more than 12 hours after onset of pain were considered ineligible for PCI if they were symptom-free on emergency department arrival.
PCI procedures. PCI procedures were performed in AMI patients treated by primary percutaneous transluminal coronary angioplasty (PTCA), in patients with refractory unstable angina and in patients with coronary artery disease (CAD) with type A lesions. Elective PCI for stable patients having B and C type lesions were referred to tertiary cen ters. PCI was not performed in patients having unstable angina if there was left main coronary artery (LMCA) dis ease (>50%), contraindications to anti-platelet therapy, or >3 stents needed for one target site.
In most cases we used Ephesus stents (Nemed Corporation, Turkey), a stainless-steel, laser-cut, tubular, slotted-tube multi-cellular device mounted on customized, non-compliant, polyethylene terephthalate, with a non-tapered short balloon overhang (0.5 mm). In the unexpended state, the crossing profile is 0.048". Clopidogrel 300 mg was administered orally before the intervention. Procedures were performed using standard angioplasty technique with an 8 French (Fr) guiding catheter via the femoral artery. A bolus of 100 IU/kg of heparin was administered intra-arterially after insertion of the vascular access sheath. Target lesions were initially treated with appropriate balloon dilatation. Intracoronary stenting was carried out after a sub-optimal result following conventional balloon angioplasty. The stent sizes were determined based on a stent-to-artery ratio of 1.1: 1 to 1.2:1. The stents were deployed at 8-14 atmospheres and high-pressure balloon inflation to 14 atmospheres was then applied with a non-compliant short balloon to avoid distal dissection.
Post-procedure medication protocol and follow-up. After successful stent implantation, heparin was not routinely administered unless there was a clinical indication, such as a large residual dissection. The sheaths were removed the same day. After sheath removal, experienced technicians per formed manual compression of the puncture site, and then applied a pressure bandage for 6 hours. Ambulation was al lowed 6 hours after sheath removal. Clopidogrel 75 mg once daily was continued for 4 weeks and aspirin 100-300 mg once daily was continued indefinitely. Electrocardiograms (ECG) were recorded immediately after the procedure, then daily before discharge. If the patient had recurrent chest pain post-procedure, a creatine kinase-myocardial band (CK-MB) level was measured and an additional ECG was recorded. The majority of patients were discharged 2 days after the procedure. Follow-up coronary angiography was performed at 6 months, or earlier if clinically indicated.
Laboratory and operators. The fluoroscopy machine was a Siemens C-800 Powermobil (Erlangen, Germany) with an X-ray generator of maximum 20 kW output. The machine has a digital cine mode with a pulse rate up to 25 frame/sec at 60 Hz. The digital processor can eliminate motion-depen dent noise. The C-arm can rotate 182o and angulate ± 190o. An ambulance was available for urgent transport. A tertiary center (Kosuyolu Heart Center, approximately 200 kilome ters away) with facilities for cardiovascular surgery for 24 hours a day was available for any urgent cases. Two experienced operators performed diagnostic coronary angiography and PCI procedures. Both had per formed more than 2000 coronary angiograms and 500 PCI procedures from January 1998 until December 2000 as the primary operator before working in the department where the study was performed. The nursing and technical cath eterization laboratory staffs were experienced in handling acutely ill patients and comfortable with interventional equipment. They participated in PCI procedures on a 24-hour, 365-day call schedule. The catheterization laboratory was well equipped with resuscitative equipment and well stocked with a broad array of interventional equipment. The cardiac care unit nurses were trained for hemodynamic monitoring.There was an ongoing program for outcome analysis and formalized periodic case review.
Definitions and angiographic analysis. Quantitative coronary angiographic analysis was performed using the quantitative coronary analysis system (AETMED S.P.a., Italy). Angiographic measurements were obtained during end-diastole using the image that showed the greatest nar rowing, without overlap and with the least degree of fore shortening. Intra-coronary nitroglycerin was administered at baseline and final angiography. Measurements of the reference vessel diameter, minimal lumen diameter (MLD) and percent diameter stenosis were determined by an aver age of two orthogonal views. The index reference diameter was the average of the proximal and distal reference vessel diameters. Lesion length was measured on the baseline an giography using the "shoulder-to-shoulder" definition. The morphology of the coronary lesions was classified as A, B1, B2 and C according to Ellis' modification of the classifica tion proposed by the American College of Cardiology and the American Heart Association Task Force.6 Changes in MLD were expressed as acute gain (post-procedural MLD minus pre-procedural MLD), late loss (post-procedural MLD minus 6-month follow-up MLD), and loss index (late loss/acute gain). Angiographic restenosis was defined as re-narrowing of the target lesion >50%. Q-wave myocardial infarction was defined as the development of new abnormal Q-waves not present at baseline in association with CK-MB enzyme elevation of three times the upper normal limit and non-q wave myocardial infarction was defined as CK and CK-MB elevation of three times the upper normal limit. Angiographic success was defined as (50% reduction in the diameter of the stenosis. Procedural success was defined as angiographic success without the occurrence of any major ischemic complications during hospitalization. A sub-opti mal result was defined as a 30-50% residual stenosis after coronary angioplasty with a TIM I 3 flow. Restenosis was defined as the occurrence of >50% stenosis at the site of angioplasty, or clinical evidence of ischemia in the territory of the dilated vessel.
Complications. Vascular complications were defined as pseudoaneurysm formation, arteriovenous fistula, thrombot ic occlusion requiring intervention and major bleeding from the puncture site necessitating blood transfusion. Major isch emic complications were defined as the occurrence of myo cardial infarction, death or the need for emergency coronary artery bypass grafting.
Data collection and statistics. Demographic, clinical and technical data were gathered retrospectively. Follow-up coro nary angiography was performed 6 months after the proce dure. Statistical analysis was performed with SPSS 10.0 for Windows. Continuous variables are expressed as mean±SD.
Results
There were no deaths, anaphylactic shock, acute renal failure or major ischemic complications in the diagnostic coronary angiography group. Two patients had femoral artery pseudoaneurysms and were treated with surgery, and two patients had strokes. One, a 68-year-old male, had LMCA disease and a right occipital lobe infarction of the Table 5 . Outcom e fo r all PCI procedures.
In-hospital outcome (n=172)(%) The mean age of the 172 PCI patients was 58.1 ± 11 years (mean±SD). There were a high proportion of patients with hypertension (40%) and diabetes mellitus (32%). Approximately half of the patients had refractory unstable angina and nearly one-third of the patients had received pri mary PTCA. Type B and C lesions were present in 36.9% of patients according to the ACC/AHA classification. The mean reference lumen diameter was 2.74±0.42 mm and 62% of the lesions were under 3 mm in diameter. In 7 cases in 172 patients the stent could not be deployed. The device success rate was 96%. The mean pressure used for stent de ployment was 11.4±2.6 atm. The acute gain was 1.43±0.48 mm. Direct stenting was feasible in 32 patients with type A lesions and predilatation of lesions was performed in the majority of patients using undersized balloons with average pressures for 60 seconds. Events such as stent lost, stent dislocation or balloon burst before optimal deployment did not occur. No acute or subacute stent thrombosis occurred. Platelet glycoprotein Ilb/IIIa receptor blockers were used in 35 (20%) patients (all tirofiban) in whom PTCA was performed in the acute phase of MI. In none of the elective procedures was the use of these agents necessary.
Early clinical outcomes of the patients are shown in Table 5 . In-hospital and procedural total mortality was 1.1% (2 patients). Both patients had acute MI complicated with cardiogenic shock on admission. One died during PCI from refractory ventricular fibrillation and the other died during hospital follow-up due to advanced low cardiac out put upon intraaortic balloon pumping. Three patients had been sent for urgent cardiac surgery because of cardiogenic shock untreatable by PCI alone. One had acute mitral re gurgitation; the second had ventricular septal rupture and the third had acute papillary muscle rupture associated with acute MI.
Discussion
Although the number of invasive procedures performed in Turkey in patients with ischemic heart disease constantly increases, it is still lower than the expected number because of limited access to catheterization laboratories. A possible solution to this problem-use of mobile angiographs in hos pitals without on-site cardiac surgery-has some drawbacks. ACC/AHA guidelines do not recommend elective PCI and primary PCI without on-site cardiac surgery except when there is a proven plan for rapid access to a cardiac surgery room within 1 hour. However, the guidelines stress that that complication rates will be subject to future revision as newer data emerge. 7 The rationale behind PCI without on-site surgery is the decrease in need for emergency coronary artery bypass, which ranges between 0.4% and 2%,8 with the advent of intracoro nary stenting. Not surprisingly, emergency coronary artery bypass for a patient with an occluded or dissected coronary artery is associated with a higher mortality than elective sur gery.9 Emergency procedures are also associated with high rates of per operative infarction and less frequent use of ar terial conduits. Complex CAD intervention, hemodynamic instability, and prolonged time to reperfusion are contrib uting factors to the increased risk of emergency bypass surgery. These data encouraged the authors to perform PCI in hospitals without on-site surgery. Many studies report successful angioplasty series without on-site surgical backup and with little need for off-site surgery in failed angioplasty. Nevertheless, the appropriateness of elective angioplasty in centers without on-site surgical coverage is a concern.10 PCI were performed in AMI patients by W harton et al. and in refractory unstable angina by Michalis et al., in hospitals without on-site surgery with excellent results.1112 Hayat et al. performed PCI in 117 consecutive patients without applying any exclusion criteria. Patients had stable angina, unstable angina and silent ischemia. Angiographic success was 91% with major complications in only four patients (1 death, 2 AMI and 1 tamponade) with no need for emergen cy surgery. 13 The ACC/AHA guidelines recommend timely management of ischemic complications, adequate special ized post-interventional care, logistics for managing cardiac surgical or vascular complications and operator/laboratory volumes.7 Interventional cardiology procedures are associ ated with complications that in general are inversely related to operator and institutional volume.14 All of the procedures in our study were performed with a mobile angiograph. While the usefulness of this type of angiograph for coronary angiography has been well docu mented, the safety and efficacy of PTCA performed with the use of mobile angiograph has been a matter of debate in the interventional cardiologist community, mainly because of certain drawbacks with this type of equipment. The main disadvantages include a less effective cooling system, which leads to the x-ray tube overheating during the longer duration of fluoroscopy, particularly during projections with the voltage close to the maximal values. There is also an increased risk of an automatic temporary switch-off due to overheating with the machine turning back on after as long as several minutes, and the inferior quality of the images in some projections and in obese patients. The ad vantages include low cost, feasibility of installation, ease of use, a modern digital recording system on CD ROM in the D ICO M system and the mobility of the apparatus.
In recent years, portable fluoroscopic imaging systems have been developed to reduce costs and bring coronary an giography services closer to patients. Vergara demonstrated the reliability of the new generation mobile systems with re spect to the quality of coronary angiograms and the routine use in a multipurpose cardiac catheterization laboratory. 15 Carosio et al compared a portable system with a station ary system, and found complete concordance between the systems for lesion location, stenosis quantification, mor phologic characterization, TIM I flow and collateral dem onstration, concluding that a portable imaging system can produce high-quality images.16 Aliabadi et al. found similar results.17 Reczuch et al. reported a mortality rate of 0.4% and a major adverse cardiac event rate of 0.9% in 687 PCI patients, including AMI patients. There was no need for urgent cardiac surgery.
The major cardiac event rate in our study was 4.5% and the in-hospital mortality rate was 1.2% after PCI. Urgent cardiac surgery was need in 1.7% of patients.18 These data are compatible with a recent study published by Anderson et al. which was based on PCI data collected and analyzed by the American College of Cardiology-National Cardiovascular Data Registry from January 1, 1998, through September 30, 2000 from 100 292 PCI procedures. Anderson et al reported 77% stent utility and an overall mortality rate of 1.4%. 19 We think that because of achievements in stent technol ogy and newly available drugs, diagnostic coronary angiogra phy can be safely performed with mobile angiographs in all patients and electively to selected patients without the need for surgical standby. However, large, prospective, random ized trials are needed to increase the evidence level for this approach.
